Efficacy and safety of aclidinium bromide 400 µg BID (twice a day)compared to placebo in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD)

Study identifier:M/34273/40

ClinicalTrials.gov identifier:NCT01471171

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A multiple dose, randomised, double-blind, placebo controlled, 2 period crossover clinical trial to assess the effect of aclidinium bromide 400 μg BID on exercise endurance in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD)

Medical condition

Chronic obstructive pulmonary disease (COPD)

Phase

Phase 3

Healthy volunteers

No

Study drug

Aclidinium Bromide, Placebo

Sex

All

Actual Enrollment

112

Study type

Interventional

Age

40 Years +

Date

Study Start Date: 01 Nov 2011
Primary Completion Date: 01 Jun 2012
Study Completion Date: 01 Jun 2012

Study design

Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Oct 2016 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria